Д. М. Дубовиченко
Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser · 32 works · 50 citations · h-index 4
Top works
- Primary epidemiological evaluation of the effectiveness of the All-National Dispensarization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry
- Cancer mortality trends after implementation of the national programme for dispensarization of certain groups of the adult population: a population-based study from arkhangelsk, north-western russia
- Incidence, mortality and determinants of survival from cervical cancer in Northwest Russia: a registry-based cohort study
- Cost of supportive cancer care in the Russian Federation. Part 1
- POPULATION-BASED ASSESSMENT OF THE RECTAL CANCER STAGE STRUCTURE AND INCIDENCE AFTER IMPLEMENTATION OF THE NATIONAL PROJECT “HEALTH” AND ALL-NATIONAL DISPENSARIZATION IN THE ARKHANGELSK REGION, RUSSIA (THE RESULTS OF THE PRELIMINARY STUDY)
- EPIDEMIOLOGY OF GASTRIC CANCER IN KAZAKHSTAN IN 2005-2014
- Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study
- Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study
- EFFECT OF NATIONAL PROGRAMS IN ONCOLOGY ON SURVIVAL OF PATIENTS WITH RECTAL CANCER: A POPULATION-BASED ANALYSIS
- Real-world outcomes of lenvatinib plus pembrolizumab in intermediateand poor-risk metastatic renal cell carcinoma
- Urban-rural variations in survival from gastric cancer in Northwest Russia: a registry-based study
- Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
- RECTAL CANCER INCIDENCE IN ARKHANGELSK REGION: TRENDS AND SHORT-TERM PROGNOSIS BY THE DATA OF THE ARKHANGELSK REGIONAL CANCER REGISTRY
- TIME TRENDS OF RECTAL CANCER INCIDENCE AND MORTALITY: A POPULATION-BASED STUDY FROM THE ARKHANGELSK REGIONAL CANCER REGISTRY
- Efficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia
- Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
- Use of empegfilgrastim for primary prevention of febrile neutropenia in patients receiving myelosuppressive therapy. Experience of the Arkhangelsk Clinical Oncological Dispensary
- 295P Real-world efficacy and safety of lenvatinib plus pembrolizumab in metastatic renal cell carcinoma patients with intermediate and poor risk
- Cost of supportive cancer care in the Russian Federation. Part 2
- Assessment of the Effect of the National Project ‘Health' on Survival among Patients with Rectal Cancer in the Arkhangelsk Region, Northwest Russia.